Compare TEX & CPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TEX | CPRX |
|---|---|---|
| Founded | 1933 | 2002 |
| Country | United States | United States |
| Employees | N/A | 167 |
| Industry | Construction/Ag Equipment/Trucks | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.7B | 2.9B |
| IPO Year | 1994 | 2006 |
| Metric | TEX | CPRX |
|---|---|---|
| Price | $67.10 | $23.91 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 2 |
| Target Price | ★ $66.67 | $32.50 |
| AVG Volume (30 Days) | ★ 2.7M | 1.2M |
| Earning Date | 05-12-2026 | 01-01-0001 |
| Dividend Yield | ★ 0.98% | N/A |
| EPS Growth | N/A | ★ 28.24 |
| EPS | ★ 3.33 | 1.68 |
| Revenue | ★ $5,421,000,000.00 | $119,072,803.00 |
| Revenue This Year | $47.78 | $7.14 |
| Revenue Next Year | $7.13 | $7.68 |
| P/E Ratio | $20.88 | ★ $14.22 |
| Revenue Growth | 5.73 | ★ 16.39 |
| 52 Week Low | $31.53 | $19.05 |
| 52 Week High | $71.50 | $26.56 |
| Indicator | TEX | CPRX |
|---|---|---|
| Relative Strength Index (RSI) | 55.22 | 49.55 |
| Support Level | $48.89 | $22.25 |
| Resistance Level | $71.50 | $24.81 |
| Average True Range (ATR) | 3.19 | 1.01 |
| MACD | -0.26 | -0.09 |
| Stochastic Oscillator | 47.15 | 61.67 |
Terex is a global manufacturer of aerial work platforms, materials processing equipment, and specialty equipment for the waste, recycling, and utility industries. Its current composition is a result of numerous acquisitions over several decades to focus on a smaller group of light construction and other vocational equipment, having divested a handful of underperforming businesses, particularly in cranes and other lifting equipment. These remaining segments see heavy demand in nonresidential construction (aerial work platforms—40% sales), aggregates/mining (materials processing—30% sales), environmental, waste/recycling and utilities (environmental solutions group—30% sales).
Catalyst Pharmaceuticals Inc is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases. The Company sells three commercial stage drug products, FIRDAPSE (amifampridine), AGAMREE (vamorolone), and FYCOMPA (perampanel). The Company is currently seeking to further expand its product portfolio, with a focus on acquiring the rights to immediately and near-term accretive assets to treat rare (orphan) diseases across therapeutic areas, including clinical-stage opportunities with established proof of concept.